Perry C.  Siatis net worth and biography

Perry Siatis Biography and Net Worth

EVP of AbbVie

Perry Siatis is Executive Vice President, General Counsel and Secretary, a member of the executive leadership team, and responsible for global legal and the office of ethics and compliance. He is credited with negotiating highly successful global business deals, navigating complex government policy, and providing strategic legal guidance for multiple billion-dollar brands. In 2020, he led the legal strategy for the acquisition of Allergan, one of the largest acquisitions in pharmaceutical history.

Mr. Siatis began his career by practicing commercial and intellectual property (IP) litigation at DLA Piper LLP. He joined Abbott in 2005 as Counsel and progressed to Division Counsel, IP Litigation and later became Divisional Vice President and Section Head, IP Strategy. In January 2013, Mr. Siatis joined AbbVie where he served as Vice President, Biologic Strategic Development and Legal Regulatory where he strengthened the legal strategy surrounding AbbVie’s premier biologic and the world’s top selling drug. Prior to his most recent role, Mr. Siatis was the Senior Vice President of Legal Transactions and R&D/Alliance Management and Chief Ethics and Compliance Officer.

Mr. Siatis is a champion of diversity and inclusion and has spearheaded AbbVie Legal engagements with Historically Black Colleges and Universities and the National Association of Minority & Women Owned Law Firms. At AbbVie, he is the executive sponsor of the ABILITY Employee Resource Group.  

Mr. Siatis earned a bachelor's degree in accounting from George Mason University and a Juris Doctorate degree from Brigham Young University.

What is Perry C. Siatis' net worth?

The estimated net worth of Perry C. Siatis is at least $1.75 million as of February 29th, 2024. Mr. Siatis owns 10,397 shares of AbbVie stock worth more than $1,752,830 as of June 15th. This net worth evaluation does not reflect any other assets that Mr. Siatis may own. Learn More about Perry C. Siatis' net worth.

How old is Perry C. Siatis?

Mr. Siatis is currently 49 years old. There are 7 older executives and no younger executives at AbbVie. The oldest executive at AbbVie is Mr. Richard A. Gonzalez, Chairman & CEO, who is 70 years old. Learn More on Perry C. Siatis' age.

How do I contact Perry C. Siatis?

The corporate mailing address for Mr. Siatis and other AbbVie executives is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. AbbVie can also be reached via phone at (847) 932-7900. Learn More on Perry C. Siatis' contact information.

Has Perry C. Siatis been buying or selling shares of AbbVie?

Perry C. Siatis has not been actively trading shares of AbbVie over the course of the past ninety days. Most recently, Perry C. Siatis sold 9,891 shares of the business's stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $177.39, for a transaction totalling $1,754,564.49. Following the completion of the sale, the executive vice president now directly owns 10,397 shares of the company's stock, valued at $1,844,323.83. Learn More on Perry C. Siatis' trading history.

Who are AbbVie's active insiders?

AbbVie's insider roster includes Carlos Alban (Vice Chairman), Roxanne Austin (Director), Kevin Buckbee (SVP), Nicholas Donoghoe (SVP), Brian Durkin (VP), Richard Gonzalez (CEO), Henry Gosebruch (EVP), Robert Michael (Vice Chairman), Scott Reents (Sr. VP & CFO ), Scott Reents (CFO), Timothy Richmond (EVP), Azita Saleki-Gerhardt (EVP), Laura Schumacher (Vice Chairman), Michael Severino (Vice Chairman), Perry Siatis (EVP), Elaine Sorg (SVP), Jeffrey Stewart (EVP), and Carrie Strom (SVP). Learn More on AbbVie's active insiders.

Are insiders buying or selling shares of AbbVie?

During the last year, insiders at the sold shares 11 times. They sold a total of 404,736 shares worth more than $70,989,822.24. The most recent insider tranaction occured on March, 20th when EVP Nicholas Donoghoe sold 21,082 shares worth more than $3,716,756.60. Insiders at AbbVie own 0.3% of the company. Learn More about insider trades at AbbVie.

Information on this page was last updated on 3/20/2024.

Perry C. Siatis Insider Trading History at AbbVie

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/29/2024Sell9,891$177.39$1,754,564.4910,397View SEC Filing Icon  
2/23/2024Sell13,753$177.51$2,441,295.0328,173View SEC Filing Icon  
4/3/2023Sell3,520$160.00$563,200.0010,377View SEC Filing Icon  
3/1/2023Sell12,135$153.08$1,857,625.8010,377View SEC Filing Icon  
See Full Table

Perry C. Siatis Buying and Selling Activity at AbbVie

This chart shows Perry C Siatis's buying and selling at AbbVie by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AbbVie Company Overview

AbbVie logo
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More

Today's Range

Now: $168.59
Low: $166.00
High: $169.24

50 Day Range

MA: $163.56
Low: $154.86
High: $170.43

2 Week Range

Now: $168.59
Low: $130.96
High: $182.89

Volume

3,933,662 shs

Average Volume

5,477,690 shs

Market Capitalization

$297.71 billion

P/E Ratio

50.03

Dividend Yield

3.73%

Beta

0.6